Haploidentical hematopoietic stem-cell transplantation in adults

Area of Science:

• Hematology
• Immunology
• Transplantation Medicine

Background:

• Haploidentical stem-cell transplantation (HSCT) is crucial for patients lacking HLA-matched donors, as suitable donors are scarce.
• Historically, HSCT faced high rates of graft rejection, graft-versus-host disease (GVHD), and transplant-related mortality.
• Significant progress in the last two decades has addressed many of these historical drawbacks.

Purpose of the Study:

• To review recent advancements in haploidentical HSCT for hematologic malignancies.
• To highlight strategies overcoming traditional HSCT limitations.
• To discuss ongoing challenges and future directions in the field.

Main Methods:

• Development of T cell depletion methods, including extensive ex vivo depletion with mega-dose stem cell administration.
• Exploration of novel approaches like partial ex vivo or in vivo alloreactive T cell depletion.
• Utilization of anti-thymocyte globulin (ATG) and combined immunosuppression in unmanipulated HSCT.

Main Results:

• Advanced T cell depletion techniques have reduced graft failure and GVHD.
• Prolonged immune deficiency and increased relapse rates persist as challenges with T cell depletion.
• Promising outcomes are observed with unmanipulated HSCT using ATG and immunosuppression in mismatched/haploidentical settings.

Conclusions:

• Haploidentical HSCT is a viable and increasingly successful strategy for hematologic malignancies.
• Further research into immune reconstitution and relapse prevention is essential.
• New strategies promise to enhance immune recovery and reduce relapse post-transplant.